retatrutide nejm 2023 obesity trial ly3437943 phase 2 The that put “24%” on the map 💉 A triple-action once-weekly injection – Retatrutide — Investigational Triple Agonist

doi: 10.3389/fimmu.2025.1709561 Received 20 September 2025 Revised 16 October 2025 Accepted 11 November 2025 Published 26 November 2025 Volume 16 - 2025 Edited by Juan Pablo de Rivero Vaccari, University of Miami, United States Reviewed by Emir Malovic, University of Illinois Chicago, United States Anna Maria Sardanelli, University of Bari Aldo Moro, Italy Updates Copyright 2025 Tu, Han, Zhang, Jia, Sun, Liu, Li, Tang and Wang

Deplete any of them and fatigue arrives as one of the earliest warning signs

GLP-1 drugs do not treat autoimmune disease directly

Ongoing Phase 3 work (tracked on ClinicalTrials.gov ) will give clearer body-composition endpoints

This post can help you determine if this nutrient could make a difference for you